自2019年12月以來(lái)，國(guó)內(nèi)外暴發(fā)了新型冠狀病毒肺炎（COVID-19）。在COVID-19的患者中，除了抗病毒治療外，還要治療并發(fā)癥，臨床需要采取聯(lián)合用藥的方式進(jìn)行治療。雖然在近期發(fā)布的指南中多次強(qiáng)調(diào)注意抗COVID-19藥物間的相互作用，但卻無(wú)相應(yīng)的詳述。主要對(duì)治療COVID-19藥物的潛在相互作用進(jìn)行綜述，以期為COVID-19的臨床安全、合理用藥提供參考。

From the December 2019, coronavirus disease 2019 (COVID-19) was outbreak at home and abroad. Besides antiviral therapy, patients should be treated for complications, therefore a combination of drugs for treatment in clinic need to be taken. Although recently published guidelines have repeatedly highlighted the drug interactions between the anti-COVID-19 medicines, it has not been detailed. The potential drug-drug interactions were reviewed of the anti-COVID-19 drugs, and in order to provide references for the clinical safety and rational use of the anti-COVID-19 drugs.

R969.2

貴州省科技支撐項(xiàng)目（黔科合支撐[2020]4Y118號(hào)）；貴州省畢節(jié)市第一人民醫(yī)院院士工作站項(xiàng)目（黔科合平臺(tái)人才[2018]55621-7）；畢節(jié)市科技局重點(diǎn)實(shí)驗(yàn)室項(xiàng)目（畢科合字[2019]1號(hào)）；畢節(jié)市醫(yī)學(xué)重點(diǎn)學(xué)科項(xiàng)目（畢衛(wèi)合字[2016]1）